【摘要】 目的 :研究氯诺昔康对脊柱关节病的疗效及安全性 ,并与萘普生进行比较。方法 :6 1例活动期脊柱关节病患者 ,随机双盲分成氯诺昔康组 31例 (8mg ,bid)和萘普生组 30例 (2 5 0mg ,bid)治疗 ,疗程为 4周。对二药治疗前后的疼痛指数进行比较。结果 :氯诺昔康和萘普生在治疗 4周的平均疼痛指数减轻分别为 30 .40和 17.5 8,显示氯诺昔康对脊柱关节病的疼痛疗效较萘普生好。氯诺昔康组和萘普生组不良事件发生率分别为 9.6 5 %和10 .0 0 % ,2组皆无严重不良事件发生。结论 :氯诺昔康对脊柱关节病具有良好的镇痛抗炎作用 ,且耐受性良好。更多还原

【Abstract】 Objective:To study the efficacy and safety of lorn ox icam,a new NSAID,in comparison with naprofen in treatment of spondyloarthropathy .Methods:The randomized,double blind study was conducted in 61 patients with spondy loarthropathy.They were randomly divided to receive lornoxicam 8mg bid or naprofen 250 mg bid for 4 weeks.Results:After 4 weeks treatment,the mean Huskinssion’s VAS for lornoxi cam and naprofen was reduced to 30.40 and 17.58 respectively and incidence of ad verse reactions for lornoxicam and naprofen was 9.65% and 10.00% respectively.Conclusion:In treatment of spondyloarthropathy,lornoxicam is more effe ctive in comparison with naprofen with mild adverse reaction.更多还原